University of California San Francisco
Give to UCSF
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapy, cancer genomics, eliminating treatment disparities and other cancer research topics at this year’s
Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug.
Eric J. Small, MD, UCSF professor of Medicine and Urology Credit: UCSFThe American Society of Clinical Oncology (ASCO) has elected Eric J. Small, MD, FASCO, to serve as its president for the term
University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.” The conference will take place online and in
A phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
UCSF Health achieves 150 robotic focal HIFU procedures for prostate cancer, pioneering precision therapy with minimal side effects, prioritizing quality of life preservation.
Benjamin N. Breyer, MD, MAS, FACS, a renowned leader in urology and urological surgery, has been appointed chair of the UCSF Department of Urology.
Engineered immune cells. Supercharged scans. Drug implants. Gene manipulators. Blood biopsies. Read how these breakthroughs are transforming cancer care.
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
Transgender women keep their prostates even after gender-affirming surgery, and the estimated risk of prostate cancer is at about 14 cases per 10,000 people.
Leading cancer researchers from UCSF will present at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, held April 14-19, 2023, in Orlando.